Misplaced Pages

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 06:04, 26 November 2021 (Add: s2cid. | Use this bot. Report bugs. | Suggested by BrownHairedGirl | Linked from User:BrownHairedGirl/Articles_with_bare_links | #UCB_webform_linked 984/2164). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Vindesine

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	AU: D
Routes of administration	Intravenous
ATC code	L01CA03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	65-75%
Metabolism	Hepatic (CYP3A4-mediated)
Elimination half-life	24 hours
Excretion	Biliary and renal
Identifiers
IUPAC name methyl (5S,7S,9S)- 9-- 5-ethyl- 5-hydroxy- 1,4,5,6,7,8,9,10-octahydro- 2H- 3,7-methanoazacycloundecinoindole- 9-carboxylate
CAS Number	53643-48-4 as salt: 59917-39-4
PubChem CID	40839
DrugBank	DB00309
ChemSpider	37302
UNII	RSA8KO39WH as salt: CPH2U7DNDY
KEGG	D01769
ChEBI	CHEBI:36373
ChEMBL	ChEMBL219146
CompTox Dashboard (EPA)	DTXSID6023739
ECHA InfoCard	100.053.330
Chemical and physical data
Formula	C43H55N5O7
Molar mass	753.941 g·mol
3D model (JSmol)	Interactive image
SMILES O=C(OC)4(c2c(c1ccccc12)CCN3C(O)(CC)C(C3)C4)c5c(OC)cc6c(c5)89(N6C)(O)(C(=O)N)(O)7(/C=C\CN(78)CC9)CC
InChI InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1 Key:HHJUWIANJFBDHT-KOTLKJBCSA-N
(verify)

Vindesine, also termed Eldisine, is a semisynthetic vinca alkaloid derived from the flowering plant Catharanthus roseus. Like the natural (e.g. vinblastine and vincristine) and semisynthetic vinca alkaloids (e.g. vinorelbine and vinflunine) derived from this plant, vindesine is an inhibitor of mitosis that is used as a chemotherapy drug. By inhibiting mitosis, vinedsine blocks the proliferation of cells, particularly the rapidly proliferation cells of certain types of cancer. It is used, generally in combination with other chemotherapeutic drugs, in the treatment of various malignancies such as leukaemia, lymphoma, melanoma, breast cancer, and lung cancer.

References

1. Mondal A, Gandhi A, Fimognari C, Atanasov AG, Bishayee A (September 2019). "Alkaloids for cancer prevention and therapy: Current progress and future perspectives". European Journal of Pharmacology. 858: 172472. doi:10.1016/j.ejphar.2019.172472. PMID 31228447. S2CID 195298770.
2. Martino E, Casamassima G, Castiglione S, Cellupica E, Pantalone S, Papagni F, Rui M, Siciliano AM, Collina S (September 2018). "Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead". Bioorganic & Medicinal Chemistry Letters. 28 (17): 2816–2826. doi:10.1016/j.bmcl.2018.06.044. PMID 30122223. S2CID 52039135.
3. https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/vindesine

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Vinca alkaloids
• Mitotic inhibitors
• Antineoplastic and immunomodulating drug stubs